Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing

Figure 3

Clinicopathological landscape of patients exhibiting FGFR2 fusion among all types of cancer. (a) Venn diagram showing the percentage distribution of tumor types with FGFR2 fusion (15 cases): GC (46.7%), CBD cancer (33.3%), sarcoma (6.7%), pancreatic cancer (6.7%), and HCC (6.7%). (b) Patient profiles, including tumor type and FGFR2 fusion partner genes (top), age and sex (middle), and MSI, TMB, and PD-L1 status (bottom). (c) FGFR2 fusions with nine different partner genes were detected: TACC2, BIVV1, BTBD16, WAC, HFM1, HOOK1, INPP5F, C10orf90, and WDF11.

(a)

(b)

(c)